News
REVB
2.150
+4.88%
0.100
12 Health Care Stocks Moving In Monday's Pre-Market Session
Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. NKGen Biotech and T2 Biosystems moved upwards. Vaxxinity stock declined by 61.3% during the session.
Benzinga · 1d ago
Weekly Report: what happened at REVB last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at REVB last week (0408-0412)?
Weekly Report · 04/15 11:30
Weekly Report: what happened at REVB last week (0401-0405)?
Weekly Report · 04/08 11:35
Revelation Biosciences: Other preliminary proxy statements
Press release · 04/05 20:44
Weekly Report: what happened at REVB last week (0325-0329)?
Weekly Report · 04/01 11:32
Weekly Report: what happened at REVB last week (0318-0322)?
Weekly Report · 03/25 11:35
Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc.
Revelation Biosciences Inc. Faces significant risk due to ongoing healthcare legislative and regulatory reforms. The uncertain future of healthcare policies may adversely impact the company's financial position and operational outcomes. The average REVB stock price target is $25.00, implying 954.85% upside potential.
TipRanks · 03/24 06:00
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
Revelation Biosciences reported earnings per share of -$8.33 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for -$13.77. Revelation Bioscience reported results for the last quarter of 2013.
Investorplace · 03/23 01:52
Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
Benzinga · 03/22 20:22
Revelation Biosciences GAAP EPS of -$8.33
Seeking Alpha · 03/22 20:20
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023. The company completed a $6.2 million public offering. Revelation is focused on harnessing the power of trained immunity for the prevention and treatment of disease. The Company has begun the first in human Phase 1 clinical study of Gemini.
Dow Jones · 03/22 20:15
Press Release: Revelation Biosciences, Inc. -2-
The company has a total assets of $12.7 billion and a total liabilities of $5.2 billion. The company is expected to make a profit in the first quarter of 2018. The Company has a long-term debt of $1.1 billion and no debt. The company's stockholders' equity will be diluted to zero at the end of the year.
Dow Jones · 03/22 20:15
*Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Dow Jones · 03/22 20:15
*Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Dow Jones · 03/22 20:15
Weekly Report: what happened at REVB last week (0311-0315)?
Weekly Report · 03/18 11:33
12 Health Care Stocks Moving In Thursday's After-Market Session
Geron stock increased by 90.8% to $3.34 during Thursday's after-market session. Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 23.16% to $300.0. DIH Holding US shares rose 10.37% during the after- market session.
Benzinga · 03/14 21:33
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers. S&P 500 Health Care Sector +0.01% to 1710.78. Pharmaceuticals, Biotechnology & Life Science contributes 0.14% to index is -0.12%.
Seeking Alpha · 03/13 14:00
Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide for systemic administration. It is being developed as a potential therapy for prevention and treatment of hospital acquired infection and organ disease. The company is also developing a potential treatment for kidney disease.
Benzinga · 03/12 10:24
Revelation Biosciences Showcases Research at Nephrology Conference
TipRanks · 03/12 10:23
More
Webull provides a variety of real-time REVB stock news. You can receive the latest news about Revelation Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About REVB
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).